Vrije Universiteit Brussel

Vib Vzw

Katholieke Universiteit Leuven, Ku Leuven R&d

Centre National De La Recherche Scientifique

Universiteit Gent

Institut National De La Recherche Agronomique

Universitéde Strasbourg

Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw

Institut Francais De La Vigne Et Du Vin

Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw

Ludwig-maximilians-universitat München

Serge Muyldermans

Bart De Strooper

Lujia Zhou

Els Marjaux

Karen Silence

Jan Steyaert

Raymond Hamers

Heinrich Leonhardt

Xavier Saelens

Christophe Ritzenthaler

Gérard Demangeat

Caroline Hemmer

Ahmed Ghannam

Léa Ackerer

Vianney Poignavent

Els Torreele

Francisco Miguel Lopez Cardoso

Ann DePicker

Viet Khong Nguyen

Ulrich Rothbauer

Miguel Cardoso

Ann De Picker

The present invention relates to GFLV virus-like particles and the uses thereof in various fields, such as the pharmaceutical, agro, or veterinary areas.

Virus-like particles and uses thereof

Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.

Single domain antibodies capable of modulating BACE activity

The present invention relates to an antibody that confers protection against influenza virus infection. More specifically, it relates to an anti-neuraminidase antibody, protecting against highly pathogenic H5N1 influenza strains. The invention relates further to the use of the antibody for prophylactic and/or therapeutic treatment of influenza virus infections, and to a pharmaceutical composition comprising the antibody.

Anti-influenza antibody

The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering.

Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof

The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof including an amino acid which is neither a charged amino acid nor a C at position 45, and including an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, the positions determined according to the Kabat numbering.

The present invention relates to fragments, especially variable fragments of immunoglobulins which are by nature devoid of light chains, these fragments being nevertheless capable of exhibiting a recognition and binding activity toward specific antigens. The present invention further relates to the use of such immunoglobulin fragments formed of at least one heavy chain variable fragment or derived therefrom, for therapeutic or veterinary purposes and especially for passive immunotherapy or serotherapy.

Recombinant bivalent monospecific immunoglobulin having at least two variable fragments of heavy chains of an immunoglobulin devoid of light chains

The invention relates to a genetically modified bacteriophage, pseudovirion or phagemid capable of entering a host cell by binding of its artificial ligand to an artificial receptor present on said host cell. The invention relates also to the use of the genetically modified bacteriophage, pseudovirion or phagemid and of the host cell to screen sequence libraries, including antibody library.

Recombinant phages capable of entering host cells via specific interaction with an artificial receptor

Growing community of inventors

Hoeilaart, Belgium

Serge Muyldermans